Water-soluble prodrugs of an Aurora kinase inhibitor.

Compound 1 (SNS-314) is a potent and selective Aurora kinase inhibitor that is currently in clinical trials in patients with advanced solid tumors. This communication describes the synthesis of prodrug derivatives of 1 with improved aqueous solubility profiles. In particular, phosphonooxymethyl-derived prodrug 2g has significantly enhanced solubility and is converted to the biologically active parent (1) following iv as well as po administration to rodents.

[1]  Kelli Sims,et al.  Fosamprenavir: Drug Development for Adherence , 2006, The Annals of pharmacotherapy.

[2]  D. Ballinari,et al.  PHA-680632, a Novel Aurora Kinase Inhibitor with Potent Antitumoral Activity , 2006, Clinical Cancer Research.

[3]  M. Shelton,et al.  Fosamprenavir : clinical pharmacokinetics and drug interactions of the amprenavir prodrug. , 2006, Clinical pharmacokinetics.

[4]  Oliver Gautschi,et al.  Aurora Kinases as Anticancer Drug Targets , 2008, Clinical Cancer Research.

[5]  J. Fechner,et al.  Pharmacokinetics and pharmacodynamics of GPI 15715 or fospropofol (Aquavan injection) - a water-soluble propofol prodrug. , 2008, Handbook of experimental pharmacology.

[6]  I. Leppik,et al.  Pharmacokinetics and safety of a phenytoin prodrug given IV or IM in patients , 1990, Neurology.

[7]  B. A. Boucher,et al.  Fosphenytoin: A Novel Phenytoin Prodrug , 1996, Pharmacotherapy.

[8]  S. Lampotang,et al.  Interactive Web Simulation for Propofol and Fospropofol, a New Propofol Prodrug , 2008, Anesthesia and analgesia.

[9]  Rajesh Odedra,et al.  AZD1152, a Selective Inhibitor of Aurora B Kinase, Inhibits Human Tumor Xenograft Growth by Inducing Apoptosis , 2007, Clinical Cancer Research.

[10]  A. Ray,et al.  Therapeutic potential of Aurora kinase inhibitors in cancer. , 2006, Current opinion in investigational drugs.

[11]  G. Schwartz,et al.  Aurora Kinases: New Targets for Cancer Therapy , 2006, Clinical Cancer Research.

[12]  J. Dumas,et al.  Recent developments in the discovery of protein kinase inhibitors from the urea class. , 2004, Current opinion in drug discovery & development.

[13]  B. Testa,et al.  Lessons learned from marketed and investigational prodrugs. , 2004, Journal of medicinal chemistry.

[14]  L. Cohen.  Clinical trial: a dose–response study of fospropofol disodium for moderate sedation during colonoscopy , 2008, Alimentary pharmacology & therapeutics.

[15]  David Bebbington,et al.  VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo , 2004, Nature Medicine.

[16]  P. D. Andrews,et al.  Aurora kinases: shining lights on the therapeutic horizon? , 2005, Oncogene.

[17]  V. Stella,et al.  Novel prodrug approach for tertiary amines: synthesis and preliminary evaluation of N-phosphonooxymethyl prodrugs. , 1999, Journal of medicinal chemistry.

[18]  A. Cho.  Recent Advances in Oral Prodrug Discovery , 2006 .

[19]  Wei Chen,et al.  Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase , 2007, Proceedings of the National Academy of Sciences.

[20]  D. Gandara,et al.  Aurora kinase inhibitors: a new class of targeted drugs in cancer. , 2006, Clinical lung cancer.

[21]  Tycho Heimbach,et al.  Prodrugs: design and clinical applications , 2008, Nature Reviews Drug Discovery.

[22]  Wang Shen,et al.  Discovery of a potent and selective aurora kinase inhibitor. , 2008, Bioorganic & medicinal chemistry letters.